STOKE THERAPEUTICS ($STOK) posted quarterly earnings results on Tuesday, August 12th. The company reported earnings of -$0.40 per share, beating estimates of -$0.52 by $0.12. The company also reported revenue of $13,820,000, beating estimates of $9,089,332 by $4,730,668.
You can see Quiver Quantitative's $STOK stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
STOKE THERAPEUTICS Insider Trading Activity
STOKE THERAPEUTICS insiders have traded $STOK stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $STOK stock by insiders over the last 6 months:
- TRUST SKORPIOS sold 3,000,000 shares for an estimated $30,599,999
- BARRY TICHO (CHIEF MEDICAL OFFICER) has made 0 purchases and 8 sales selling 51,071 shares for an estimated $520,636.
- EDWARD M. MD KAYE has made 0 purchases and 2 sales selling 19,289 shares for an estimated $163,672.
- JONATHAN ALLAN (GENERAL COUNSEL & CORP SEC) has made 0 purchases and 2 sales selling 4,211 shares for an estimated $35,731.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
STOKE THERAPEUTICS Hedge Fund Activity
We have seen 67 institutional investors add shares of STOKE THERAPEUTICS stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SKORPIOS TRUST removed 3,650,000 shares (-52.9%) from their portfolio in Q2 2025, for an estimated $41,427,500
- FMR LLC added 2,376,741 shares (+1438.7%) to their portfolio in Q1 2025, for an estimated $15,805,327
- MARSHALL WACE, LLP added 1,180,351 shares (+124.1%) to their portfolio in Q1 2025, for an estimated $7,849,334
- BANK OF AMERICA CORP /DE/ added 523,793 shares (+5761.7%) to their portfolio in Q1 2025, for an estimated $3,483,223
- CHECKPOINT CAPITAL L.P. added 425,330 shares (+139.3%) to their portfolio in Q1 2025, for an estimated $2,828,444
- ASSENAGON ASSET MANAGEMENT S.A. removed 421,630 shares (-43.9%) from their portfolio in Q2 2025, for an estimated $4,785,500
- ERSTE ASSET MANAGEMENT GMBH added 396,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,633,400
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
STOKE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $STOK in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 07/18/2025
- Needham issued a "Buy" rating on 07/01/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/14/2025
- Chardan Capital issued a "Buy" rating on 03/19/2025
To track analyst ratings and price targets for STOKE THERAPEUTICS, check out Quiver Quantitative's $STOK forecast page.
STOKE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $STOK recently. We have seen 4 analysts offer price targets for $STOK in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Andrew Tsai from Jefferies set a target price of $30.0 on 07/18/2025
- Joseph Stringer from Needham set a target price of $22.0 on 07/01/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $35.0 on 05/14/2025
- Rudy Li from Chardan Capital set a target price of $24.0 on 03/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
